BR112022011838A2 - Derivados de benzimidazol - Google Patents

Derivados de benzimidazol

Info

Publication number
BR112022011838A2
BR112022011838A2 BR112022011838A BR112022011838A BR112022011838A2 BR 112022011838 A2 BR112022011838 A2 BR 112022011838A2 BR 112022011838 A BR112022011838 A BR 112022011838A BR 112022011838 A BR112022011838 A BR 112022011838A BR 112022011838 A2 BR112022011838 A2 BR 112022011838A2
Authority
BR
Brazil
Prior art keywords
benzimidazole derivatives
benzimidazoles
processes
formula
same
Prior art date
Application number
BR112022011838A
Other languages
English (en)
Inventor
William Bagley Scott
Casimiro-Garcia Agustin
Cheng Xiayun
Elizabeth Davoren Jennifer
Aldrin Denny Rajiah
Stephen Gerstenberger Brian
Eldridge Lovering Frank
Dineshkumar Parikh Mihir
Walter Strohbach Joseph
Isidro Trujillo John
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112022011838A2 publication Critical patent/BR112022011838A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

DERIVADOS DE BENZIMIDAZOL. A presente invenção refere-se a benzimidazóis de Fórmula (I) e sais farmaceuticamente aceitáveis dos mesmos, em que R1 a R6 são como definidos no relatório descritivo; ao seu uso em medicina; a composições contendo os mesmos, a processos para a preparação dos mesmos; e a intermediários usados em tais processos. Os benzimidazóis de Fórmula (I) são inibidores de ITK e são, portanto, potencialmente úteis no tratamento de uma ampla gama de distúrbios, incluindo dermatite atópica.
BR112022011838A 2019-12-20 2020-12-16 Derivados de benzimidazol BR112022011838A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951030P 2019-12-20 2019-12-20
US202063108602P 2020-11-02 2020-11-02
PCT/IB2020/062036 WO2021124155A1 (en) 2019-12-20 2020-12-16 Benzimidazole derivatives

Publications (1)

Publication Number Publication Date
BR112022011838A2 true BR112022011838A2 (pt) 2022-08-30

Family

ID=73856233

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011838A BR112022011838A2 (pt) 2019-12-20 2020-12-16 Derivados de benzimidazol

Country Status (19)

Country Link
US (1) US11661419B2 (pt)
EP (1) EP4077316A1 (pt)
JP (1) JP2023507138A (pt)
KR (1) KR20220118525A (pt)
CN (1) CN115087655A (pt)
AU (1) AU2020405536B2 (pt)
BR (1) BR112022011838A2 (pt)
CA (1) CA3103120A1 (pt)
CL (1) CL2022001675A1 (pt)
CO (1) CO2022008313A2 (pt)
CR (1) CR20220299A (pt)
DO (1) DOP2022000130A (pt)
EC (1) ECSP22049160A (pt)
IL (1) IL293831B2 (pt)
MX (1) MX2022007518A (pt)
PE (1) PE20221916A1 (pt)
TW (1) TWI766484B (pt)
UY (1) UY38998A (pt)
WO (1) WO2021124155A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3205020A1 (en) * 2020-12-15 2022-06-23 Pfizer Inc. Benzimidazole derivatives and their use as inhibitors of itk for the treatment of skin disease
CN114624358A (zh) * 2022-03-11 2022-06-14 哈尔滨圣泰生物制药有限公司 一种地氯雷他定口服液的质量检测方法
WO2023249992A2 (en) * 2022-06-21 2023-12-28 Jjr&D, Llc Topical benzimidazole formulations and methods for use in treating inflammatory dermatoses

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
AU2002334217B2 (en) * 2001-10-26 2008-07-03 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
JP2007533753A (ja) 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
TW200719899A (en) 2005-04-14 2007-06-01 Hoffmann La Roche Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
GB0602178D0 (en) 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
US20080070933A1 (en) 2006-08-24 2008-03-20 Huang Kenneth H Purine, Pyrimidine, and Azaindole Derivatives
CN101952294B (zh) 2008-02-25 2014-11-26 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
EP2245033B1 (en) 2008-02-25 2011-08-31 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
BRPI0907928A2 (pt) 2008-02-25 2015-07-28 Hoffmann La Roche Inibidores de pirrolopirazina quinase.
WO2009106445A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
EP2247592B1 (en) 2008-02-25 2011-08-31 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
EP2196458A1 (en) 2008-12-10 2010-06-16 Laboratorios Del. Dr. Esteve, S.A. Process for obtaining enantiomerically enriched pyrazole derivatives
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2292237A1 (en) 2009-08-14 2011-03-09 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention or treatment of pain induced by chemotherapy
US8299070B2 (en) 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
US8481541B2 (en) 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
CA2798970A1 (en) 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives as syk and jak inhibitors
AU2011269989B2 (en) * 2010-06-23 2014-12-11 Hanmi Science Co., Ltd. Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2455081A1 (en) 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of crohn's disease
EP2455080A1 (en) 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
PL2672967T3 (pl) 2011-02-07 2019-04-30 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania ku temu
CA2843499A1 (en) 2011-08-12 2013-02-21 F. Hoffmann-La Roche Ag Indazole compounds, compositions and methods of use
RU2673064C2 (ru) 2011-09-01 2018-11-22 Ф. Хоффманн-Ля Рош Аг Пирролопиразиновые ингибиторы киназы
WO2014023258A1 (en) 2012-08-10 2014-02-13 F.Hoffmann-La Roche Ag Pyrazole carboxamide compounds, compositions and methods of use
WO2014041518A1 (en) 2012-09-14 2014-03-20 Glenmark Pharmaceuticals S.A. Thienopyrrole derivatives as itk inhibitors
CN104640858B (zh) 2012-09-26 2018-11-06 霍夫曼-拉罗奇有限公司 环醚吡唑-4-基-杂环基-甲酰胺化合物及使用方法
CN103804364A (zh) 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103804361A (zh) 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800328A (zh) 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804291A (zh) 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800337A (zh) 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800327A (zh) 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103800340A (zh) 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804302A (zh) 2012-11-14 2014-05-21 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103804351A (zh) 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804363A (zh) 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804272A (zh) 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN104628657A (zh) 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
WO2016001341A1 (en) 2014-07-03 2016-01-07 F. Hoffmann-La Roche Ag Sulfonylaminopyridine compounds, compositions and methods of use
CN110845482B (zh) 2014-07-04 2024-01-19 日本烟草产业株式会社 制备吲哚化合物的方法
WO2016010108A1 (ja) 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
CN105524067A (zh) 2014-09-28 2016-04-27 江苏柯菲平医药股份有限公司 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
WO2016091916A1 (en) 2014-12-10 2016-06-16 F. Hoffmann-La Roche Ag Pyrazolylaminopurines as itk inhibitors
US10618914B2 (en) 2015-01-15 2020-04-14 University of Pittsburgh—of the Commonwealth System of Higher Education 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-B][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity
CA2988601C (en) 2015-07-02 2021-12-07 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
WO2019225740A1 (ja) 2018-05-25 2019-11-28 日本たばこ産業株式会社 インドール化合物を含む多発性硬化症の治療又は予防剤
EP3804727B1 (en) 2018-05-25 2023-10-11 Japan Tobacco Inc. Indol-containing compound for use in the treatment of the nephrotic syndrome
EP3801546A1 (en) 2018-05-25 2021-04-14 Japan Tobacco Inc. Method of treating pain or interstitial cystitis using indole compound
CA3205020A1 (en) * 2020-12-15 2022-06-23 Pfizer Inc. Benzimidazole derivatives and their use as inhibitors of itk for the treatment of skin disease

Also Published As

Publication number Publication date
US20210188829A1 (en) 2021-06-24
IL293831B1 (en) 2023-10-01
TW202130634A (zh) 2021-08-16
CL2022001675A1 (es) 2023-03-17
EP4077316A1 (en) 2022-10-26
CN115087655A (zh) 2022-09-20
ECSP22049160A (es) 2022-07-29
TWI766484B (zh) 2022-06-01
AU2020405536A1 (en) 2022-07-14
CO2022008313A2 (es) 2022-07-08
IL293831B2 (en) 2024-02-01
AU2020405536B2 (en) 2023-09-07
CR20220299A (es) 2022-08-05
UY38998A (es) 2021-07-30
CA3103120A1 (en) 2021-06-20
KR20220118525A (ko) 2022-08-25
IL293831A (en) 2022-08-01
JP2023507138A (ja) 2023-02-21
US11661419B2 (en) 2023-05-30
WO2021124155A1 (en) 2021-06-24
MX2022007518A (es) 2022-09-19
PE20221916A1 (es) 2022-12-23
DOP2022000130A (es) 2022-07-31

Similar Documents

Publication Publication Date Title
BR112022011838A2 (pt) Derivados de benzimidazol
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
BR112016016844A2 (pt) Compostos heterocíclicos
BR112018077015A2 (pt) derivados de ácido borônico e usos terapêuticos dos mesmos
CO7350655A2 (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
EA201591339A1 (ru) Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
BR112014000713A2 (pt) derivados de indol substituído como moduladores de gama secretase
BR112018076169A2 (pt) derivados azabenzimidazol como inibidores de pi3k beta
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
NZ726052A (en) Phosphatidylinositol 3-kinase inhibitors
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
BR112017026224A2 (pt) moduladores de ror gama (rory)
DOP2018000035A (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
UY31865A (es) Derivados de urea heterocíclicos y métodos para la utilización de los mismos
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
CO2023008921A2 (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas
ECSP21037191A (es) Pirazoles como moduladores de la hemoglobina
BR112015031846A8 (pt) derivados de estratrientiazol, seus usos, e composição farmacêutica
CO2023017151A2 (es) Inhibidores de ripk1 de nicotinamida
BR112023017040A2 (pt) Derivados de indolina como inibidores de ddr1 e ddr2
BR112022005723A2 (pt) Compostos de indol carboxamida e seu uso para o tratamento de infecções micobacterianas

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: PFIZER INC. (US)

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]